Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (MACARONI-23)

Last Updated   April 23, 2025

Want to learn how to participate in this trial?

CR109212

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    2+ years
  • Phase
    phase 3
    3
  • Sites
    63 Sites
  • Status
    Recruiting

SUMMARY

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

CONDITIONS

  • Crohn's Disease

ELIGIBILITY


Inclusion Criteria:

* Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
* Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
* Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
* Participants must have a prior or current CD medication history that includes either inadequate response, loss of response to or failure to tolerate current treatment immunomodulators or with oral or intravenously (IV) corticosteroids or have received biologic therapy/JAK inhibitor for the treatment of CD and have a documented history of inadequate response, loss of response (LOR), or intolerance to the biologic therapy/JAK inhibitor


Exclusion Criteria:

* Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
* Participants must not have an abscess
* Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline


Inclusion Criteria:

* Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
* Participants must have moderately to severely ac

More...

DETAILS

LOCATIONS

Locations in:
United States, France, Italy, Japan, Norway, Poland, Spain, United Kingdom, Belgium, Austria, Brazil, Israel, South Korea, Netherlands, Portugal
Country (15) City or Province (63) Status
United States Atlanta Emory University
RECRUITING
United States Atlanta Children's Center for Digestive Health Care
RECRUITING
United States Indianapolis Riley Hospital for Children
RECRUITING
United States New York Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
RECRUITING
France Lille Hôpital Jeanne de FLANDRE, CHRU LILLE
RECRUITING
Italy Firenze Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
RECRUITING
Italy Roma AOU Policlinico Umberto I
RECRUITING
Japan Hirosaki Hirosaki University Hospital
RECRUITING
Japan Kashiwa-shi Tsujinaka Hospital Kashiwanoha
RECRUITING
Japan Saga Saga University Hospital
RECRUITING
Japan Sendai Miyagi Children's Hospital
RECRUITING
Japan Setagaya Ku National Center for Child Health and Development
RECRUITING
Japan Tokyo Juntendo University Hospital
RECRUITING
Japan Yokohama-shi Yokohama City University Medical Center
RECRUITING
Norway Nordbyhagen Akershus Universitetssykehus HF
RECRUITING
Norway Oslo Oslo University Hospital
RECRUITING
Norway Tromsø Universitetssykehuset Nord-Norge HF
RECRUITING
Norway Trondheim St. Olavs Hospital
RECRUITING
Poland Rzeszow Korczowski Bartosz Gabinet Lekarski
RECRUITING
Spain Valencia Hosp. Univ. I Politecni La Fe
RECRUITING
United Kingdom Sheffield Sheffield Children's Hospital
RECRUITING
Belgium Gent Universitair Ziekenhuis Gent
RECRUITING
United States Hartford Connecticut Children's Medical Center
RECRUITING
United States New York Columbia University Medical Center
RECRUITING
United States Philadelphia Children's Hospital of Philadelphia
RECRUITING
United States Colchester University of Vermont Medical Center
RECRUITING
Austria Vienna AKH - Medizinische Universitat Wien
RECRUITING
Belgium Brussels Universitair Ziekenhuis Brussel
RECRUITING
Belgium Bruxelles Cliniques Universitaires Saint Luc
RECRUITING
Brazil Campinas Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
RECRUITING
Brazil Curitiba Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
RECRUITING
Brazil Goiania Universidade Federal de Goias - Hospital das Clinicas da UFG
RECRUITING
Brazil Porto Alegre Irmandade Santa Casa de Misericordia de Porto Alegre
RECRUITING
Brazil Vitória Centro de Ciências e Saúde da Universidade Federal do Espirito Santo-Núcleo de Doenças Infecciosas
RECRUITING
Brazil Votuporanga INTEGRAL Pesquisa e Ensino
RECRUITING
France Amiens Cedex 1 CHU Amiens-Hopital Nord
RECRUITING
France Paris cedex 15 Hôpital Necker - Enfants Malades
RECRUITING
France Paris Hôpital Robert Debré
RECRUITING
Israel Be Er Ya Akov Shamir Medical Center Assaf Harofeh
RECRUITING
Israel Beersheba Soroka University Medical Center
RECRUITING
Israel Jerusalem Shaare Zedek Medical Center
RECRUITING
Israel Jerusalem Hadassah Medical Center
RECRUITING
Israel Petach-Tikva Schneider Children's Medical Center
RECRUITING
Italy Bergamo Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
RECRUITING
Italy Bologna Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
RECRUITING
Italy Milano Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
RECRUITING
South Korea Busan Inje University Haeundae Paik Hospital
RECRUITING
South Korea Daegu Kyungpook National University Chilgok Hospital
RECRUITING
South Korea Seoul Seoul National University Hospital
RECRUITING
South Korea Seoul Samsung Medical Center
RECRUITING
South Korea Seoul Severance Hospital Yonsei University Health System
RECRUITING
Netherlands Rotterdam Erasmus Medisch Centrum
RECRUITING
Poland Warszawa WIP Warsaw IBD Point Profesor Kierkus
RECRUITING
Poland Warszawa Instytut Pomnik Centrum Zdrowia
RECRUITING
Portugal Braga Hospital de Braga
RECRUITING
Portugal Lisboa Centro Hospitalar de Lisboa Norte Hospital Santa Maria
RECRUITING
Portugal Porto Centro Hospitalar de Sao Joao E.P.E.
RECRUITING
Spain Córdoba Hosp Reina Sofia
RECRUITING
Spain Sabadell Corporacio Sanitari Parc Tauli
RECRUITING
United Kingdom Glasgow Royal Hospital for Sick Children
RECRUITING
United Kingdom London Great Ormond Street Hospital
RECRUITING
United Kingdom Manchester Royal Manchester Children's Hospital
RECRUITING
United Kingdom Oxford John Radcliffe Hospital
RECRUITING
Show More
Geo Locations

33.749, -84.38798

33.749, -84.38798

39.76838, -86.15804

40.71427, -74.00597

50.63297, 3.05858

43.77925, 11.24626

41.89193, 12.51133

40.59306, 140.4725

35.86224, 139.97732

33.23333, 130.3

38.26667, 140.86667

35.64825, 139.65376

35.6895, 139.69171

35.43333, 139.65

59.9306759, 10.9917067

59.91273, 10.74609

69.6489, 18.95508

63.43049, 10.39506

50.04132, 21.99901

39.46975, -0.37739

53.38297, -1.4659

51.05, 3.71667

41.76371, -72.68509

40.71427, -74.00597

39.95233, -75.16379

44.54394, -73.14791

48.20849, 16.37208

50.85045, 4.34878

50.85045, 4.34878

-22.90556, -47.06083

-25.42778, -49.27306

-16.67861, -49.25389

-30.03306, -51.23

-20.31944, -40.33778

-20.42278, -49.97278

49.9, 2.3

48.85341, 2.3488

48.85341, 2.3488

31.943507, 34.83904

31.25181, 34.7913

31.76904, 35.21633

31.76904, 35.21633

32.08707, 34.88747

45.69601, 9.66721

44.49381, 11.33875

45.46427, 9.18951

35.10278, 129.04028

35.87028, 128.59111

37.566, 126.9784

37.566, 126.9784

37.566, 126.9784

51.9225, 4.47917

52.22977, 21.01178

52.22977, 21.01178

41.55032, -8.42005

38.71667, -9.13333

41.14961, -8.61099

37.89155, -4.77275

41.54329, 2.10942

55.86515, -4.25763

51.50853, -0.12574

53.48095, -2.23743

51.75222, -1.25596

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.